Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy
Abstract Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of B cell and plasma cell malignancies, and numerous promising targets against solid tumours are being explored. Despite their initial therapeutic success in hematological cancers, relapse occurs in a significan...
Saved in:
| Main Authors: | Yufei Lu, Fu Zhao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Molecular Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12943-025-02334-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tandem CAR-T cell therapy: recent advances and current challenges
by: Sara Gómez-Melero, et al.
Published: (2025-02-01) -
Study of the suppression of a tumor growth expressing a carcinoembryonic antigen with a new high-tech drug carplasmin (CAR-T therapy) in Balb/c nude mice
by: V. K. Bozhenko, et al.
Published: (2023-04-01) -
CAR-T: from bench to bedside
by: M. О. Popova, et al.
Published: (2024-09-01) -
CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges
by: Yexin Zhou, et al.
Published: (2024-11-01) -
Tandem CAR T-cells targeting CD19 and NKG2DL can overcome CD19 antigen escape in B-ALL
by: Jennifer Bolsée, et al.
Published: (2025-05-01)